Ftse Mib
33.537,74
0,96%
DAX
18.174,88
0,59%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
65.644,28
1,04%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Esperion Therapeutics Inc (ESPR) Esperion Therapeutics Inc (ESPR) Notizie

Esperion Therapeutics Inc

ESPR
2,72
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:12:42
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/6/202421:19EDGAR2Form 144 - Report of proposed sale of securities
18/6/202421:09EDGAR2Form 144 - Report of proposed sale of securities
28/5/202422:16EDGAR2Form 8-K - Current report
24/5/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202422:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202415:00GLOBEEsperion to Participate in Upcoming June Investor..
22/5/202414:00GLOBEFirst-In-Class Cholesterol-Lowering Treatment NILEMDO®..
20/5/202422:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202412:00GLOBEBempedoic Acid Met Primary Endpoint of Phase 3 Trial in..
17/5/202421:08EDGAR2Form 144 - Report of proposed sale of securities
14/5/202414:00GLOBEEsperion Receives Five Year Patent Extension for Bempedoic..
10/5/202422:00GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
08/5/202422:31EDGAR2Form 8-K - Current report
07/5/202414:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/5/202413:29EDGAR2Form 8-K - Current report
07/5/202412:00GLOBEEsperion Reports First Quarter 2024 Financial Results
29/4/202414:00GLOBEEsperion to Participate in Upcoming May Investor Conferences
23/4/202414:00GLOBEEsperion to Report First Quarter 2024 Financial Results on..
07/4/202420:45GLOBEEsperion Presents Important New Data from CLEAR Outcomes at..
01/4/202414:00GLOBEEsperion to Ring Nasdaq Opening Bell Today, April 1, 2024
26/3/202413:00GLOBEEsperion to Participate in 23rd Annual Needham Virtual..
25/3/202421:00GLOBEEsperion Announces Data from CLEAR Outcomes Sub-Groups as..
22/3/202423:26BWU.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL®..
22/3/202420:10GLOBEU.S. FDA Approves Broad New Labels for NEXLETOL® and..
22/3/202416:04GLOBECHMP Issues Positive Opinions For Both Bempedoic Acid And..
27/2/202415:19EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:23EDGAR2Form 8-K - Current report
27/2/202412:00GLOBEEsperion Reports Fourth Quarter and Full Year 2023 Financial..
16/2/202422:30GLOBEEsperion Announces Inducement Grants Under NASDAQ Listing..
14/2/202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:50EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202414:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202412:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202414:00GLOBEEsperion to Report Fourth Quarter and Full Year 2023..
01/2/202420:00GLOBERFK, Esperion Therapeutics Announce 2024 Promotional..
23/1/202422:00GLOBEEsperion Announces Closing of Public Offering of Common..
22/1/202412:10EDGAR2Form 8-K - Current report
22/1/202412:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202403:15GLOBEEsperion Announces Pricing of $85.1 Million Public Offering..
18/1/202422:03EDGAR2Form 8-K - Current report
18/1/202422:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/1/202422:00GLOBEEsperion Announces Proposed Public Offering of Common Stock
11/1/202422:09EDGAR2Form 8-K - Current report
03/1/202421:15BWEsperion e Daiichi Sankyo Europe annunciano un emendamento..
03/1/202419:54BWEsperion et Daiichi Sankyo Europe annoncent une révision de..
03/1/202416:07BWEsperion und Daiichi Sankyo Europe geben Anpassung ihrer..
03/1/202414:00EDGAR2Form 8-K - Current report
03/1/202413:00BWEsperion and Daiichi Sankyo Europe Announce $125 Million..
18/12/202314:00GLOBEEsperion to Participate in 42nd Annual J.P. Morgan..
Apertura: Min: Max:
Chiusura: 2,72

La tua Cronologia

NASDAQ
ESPR
Esperion Therapeutics
TG
J06
Aegon
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network